

-177-

7. The method of Claim 1 wherein the antineoplastic agent is Cell Pathways CP-461.

8. The method of Claim 1 wherein the antineoplastic agent is docetaxel.

5 9. The method of Claim 1 wherein the antineoplastic agent is doxorubicin.

10. The method of Claim 1 wherein the antineoplastic agent is etoposide.

11. The method of Claim 1 wherein the  
10 antineoplastic agent is fluoxymestrine.

12. The method of Claim 1 wherein the antineoplastic agent is gemcitabine.

13. The method of Claim 1 wherein the antineoplastic agent is goserelin.

15 14. The method of Claim 1 wherein the antineoplastic agent is irinotecan.

15. The method of Claim 1 wherein the antineoplastic agent is ketoconazole.

16. The method of Claim 1 wherein the  
20 antineoplastic agent is letrozol.

17. The method of Claim 1 wherein the antineoplastic agent is leucovorin.

18. The method of Claim 1 wherein the antineoplastic agent is levamisole.

25 19. The method of Claim 1 wherein the antineoplastic agent is megestrol.

20. The method of Claim 1 wherein the antineoplastic agent is mitoxantrone.

21. The method of Claim 1 wherein the  
30 antineoplastic agent is paclitaxel.

22. The method of Claim 1 wherein the antineoplastic agent is raloxifene.

23. The method of Claim 1 wherein the antineoplastic agent is retinoic acid.

5           24. The method of Claim 1 wherein the  
antineoplastic agent is tamoxifen.

25. The method of Claim 1 wherein the antineoplastic agent is thiotepa.

26. The method of Claim 1 wherein the  
10 antineoplastic agent is topotecan.

27. The method of Claim 1 wherein the antineoplastic agent is toremifene.

28. The method of Claim 1 wherein the antineoplastic agent is vinorelbine.

15            29. The method of Claim 1 wherein the  
              antineoplastic agent is vinblastine.

30. The method of Claim 1 wherein the antineoplastic agent is vincristine.

31. The method of Claim 1 wherein the  
20 antineoplastic agent is selenium (selenomethionine).


32. The method of Claim 1 wherein the antineoplastic agent is sulindac sulfone.

33. The method of Claim 1 wherein the antineoplastic agent is eflornithine (DFMO).

25            34. The method of Claim 1 wherein the  
cyclooxygenase-2 inhibitor is selected from compounds,  
and their pharmaceutically acceptable salts thereof, of  
the group consisting of:

-179-

1)



JTE-522, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-  
2-fluorobenzenesulfonamide,

5

2)


5-chloro-3-(4-(methylsulfonyl)phenyl)-2-  
(methyl-5-pyridinyl)pyridine,

3)

2-(3,5-difluorophenyl)-3-4-  
(methylsulfonyl)phenyl)-2-cyclopenten-1-one,

10

4)



4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-  
pyrazol-1-yl]-benzenesulfonamide,